前列腺癌的神经内分泌转移是动态的,依赖于ASCL1
原文发布日期:2024-10-11
英文摘要:
摘要翻译:
原文链接:
The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1
Lineage plasticity is a hallmark of cancer progression that impacts therapy outcomes, yet the mechanisms mediating this process remain unclear. Here, we introduce a versatile in vivo platform to interrogate neuroendocrine lineage transformation throughout prostate cancer progression. Transplanted mouse prostate organoids with human-relevant driver mutations (Rb1−/−; Trp53−/−; cMyc+ or Pten−/−; Trp53−/−; cMyc+) develop adenocarcinomas, but only those with Rb1 deletion advance to aggressive, ASCL1+ neuroendocrine prostate cancer (NEPC) resistant to androgen receptor signaling inhibitors. Notably, this transition requires an in vivo microenvironment not replicated by conventional organoid culture. Using multiplexed immunofluorescence and spatial transcriptomics, we reveal that ASCL1+ cells arise from KRT8+ luminal cells, progressing into transcriptionally heterogeneous ASCL1+;KRT8− NEPC. Ascl1 loss in established NEPC causes transient regression followed by recurrence, but its deletion before transplantation abrogates lineage plasticity, resulting in castration-sensitive adenocarcinomas. This dynamic model highlights the importance of therapy timing and offers a platform to identify additional lineage plasticity drivers.
线粒体可塑性是前列腺癌进展的关键特征之一,它影响着治疗效果,但这一过程中的机制尚不清楚。在这里,我们引入了一个多用途的体内平台,用于研究前列腺癌进展过程中神经内分泌转化过程。将小鼠前列腺组织球移植到含有人类相关驱动突变(如Rb1−/−、Trp53−/−、cMyc+或Pten−/−;Trp53−/−、cMyc+)的环境中,这些组织球会发育为腺癌,但只有带有Rb1缺失的才能发展成为易受雄激素受体信号抑制剂抵抗的激进型神经内分泌前列腺癌(NEPC),这种NEPC具有ASCL1+特性。值得注意的是,这一转化过程需要一种体内微环境,而这在常规组织球培养中无法实现。通过多谱系免疫荧光和空间转录组学分析发现,ASCL1+细胞来自于KRT8+/基底细胞,进而发展成为表观遗传状态各异的ASCL1+;KRT8− NEPC。Ascl1缺失在NEPC中的发生会导致暂时性退行然后复发生长,但若在移植前删除其表达,则会抑制神经内分泌转化过程,从而导致雄激素敏感性腺癌。这个动态模型凸显了治疗时机的重要性,并提供了一个研究更多进化的驱动因素的平台。
……